Eli Lilly and Company (LLY)
Why Eli Lilly Stock's Big Jump Last Week Could Be Just the Beginning of Another Huge Run
Lilly's Mounjaro and Zepbound are only warming up. The company has several other promising drugs in its lineup and pipeline.
Should Investors Buy Eli Lilly's (LLY) Stock After Strong Q2 Results?
As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.
5 ETFs to Make the Most of Eli Lilly's Strength
Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.
Eli Lilly Q2 Earnings: Thanks To Tirzepatide, $1 Trillion Valuation Now In Sight
Eli Lilly and Company reported strong Q2 2024 earnings with revenues up 36% year-on-year, exceeding expectations. Guidance for 2024 was raised by ~$3bn with expectations of $45.4bn — $46.6bn in revenues and EPS of $15.1 — $15.6 on a GAAP basis. Tirzepatide, a key revenue contributor, shows enormous potential in the diabetes and weight loss markets, driving Lilly's share price and market cap valuation.
International Markets and Lilly (LLY): A Deep Dive for Investors
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Is Eli Lilly a Stock To Buy and Hold Forever?
Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains.
Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)
Eli Lilly and Company triggered a Buy signal after a price pop from the latest earnings report. Technical Buy signals, including Full Stochastic and MACD crossover, indicate upward momentum and potential test of the recent high in price. Portfolio managers may need to sell Eli Lilly stock due to high exposure, potentially slowing bounce in a bear market.
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
The recent sell-off brought biopharma stocks down by a bit. Nothing has changed about their ability to compete.
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
Eli Lilly And Co LLY reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion.
Eli Lilly Stock Keeps Climbing After Drugmaker's Strong Earnings Report
Investors of Eli Lilly (LLY) continued to ride the wave created by the pharmaceutical firm's powerhouse second-quarter earnings report.
3 Dynamite Stocks to Load Up On For the Next Major Bull Market Rally
Long-term stocks, or those that are meant to be held for over a year, let investors ignore daily market fluctuations.
